glp-1 obesity drug news october 2025 From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of in adults 1 in 10 Americans Has

Joint discomfort is not listed as a recognised adverse effect in the BNF or licensed B12 product information, and most people taking B12 experience no musculoskeletal symptoms

Sublingual formulations (tablets or sprays placed under the tongue) are marketed as having superior absorption, but current evidence does not conclusively demonstrate that they offer significant advantages over standard oral tablets

Throughout the Day: Stay active and keep your water intake high

Interestingly, the inhibition of NF-B and certain cytoskeletal signalling enzymes restrict TJ disassembly and disruption, thereby restricting the paracellular translocation of L